Phase 2, Randomized, Double-blind, Placebo-controlled Study of Fiztasovimab (NPC-21) for Kidney Transplant Recipients at High Risk of Cytomegalovirus Infection (LionHeart21)
NPC-21 was safe, but no significant efficacy difference was found between NPC-21 and placebo. Severe CMV infection was less likely in the NPC-21 group versus the placebo group. Further studies are needed to elucidate the role of NPC-21 in the prevention of CMV.
Authors
- Yoichiro Natori (ORCID: https://orcid.org/0000-0002-4938-125X)
- Rita R. Alloway (ORCID: https://orcid.org/0000-0003-4835-9197)
- Natalia E. Castillo Almeida (ORCID: https://orcid.org/0000-0002-9904-7137)
- Tatsuya Watanabe (ORCID: https://orcid.org/0000-0001-6841-2587)
- Naotsugu Ichimaru
- Hiroto Egawa (ORCID: https://orcid.org/0000-0003-2573-4548)
- David Wojciechowski (ORCID: https://orcid.org/0000-0003-2664-507X)
- Ken Nakagawa (ORCID: https://orcid.org/0000-0002-9090-6273)
- Kenta Futamura
Institutions
- University of Miami (US)
- Jackson Health System (US)
- Tokyo Dental College Ichikawa General Hospital (JP)
- Hamamatsu Rosai Hospital (JP)
- Kinki Central Hospital (JP)
- Miami Transplant Institute (US)
- University of Nebraska Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Transplantation
- Published
- 2025-03-12
- DOI
- https://doi.org/10.1097/tp.0000000000005260
- Citations
- 1
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Japan Agency for Medical Research and Development